Study of NKTR 255 in Combination With Cetuximab in Solid Tumors

Exclusion Criteria

• •Use of an investigational agent or an investigational device within 28 days before administration of first dose of study drug(s)
• •Prior surgery or radiotherapy within 14 days of initiating study drug(s)
• •Evidence of clinically significant interstitial lung disease or active, noninfectious pneumonitis; active infection requiring systemic therapy within 7 days prior to dosing
• •Patients who have been previously treated with IL-2 or IL-15
• •Known Grade 3 or 4 hypersensitivity reaction to cetuximab, history of allergy to red meat or tick bites, or history of positive test results for immunoglobulin E antibodies against cetuximab
• •Patients who have an active, known, or suspected autoimmune disease